Navigation Links
TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
Date:1/12/2010

SCOTTSDALE, Ariz., and LONDON, Ontario Jan. 12, 2010 TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

This easily synthesized small molecule compound was discovered and developed by COTI of London, Ontario, Canada. This working relationship resulted through the expanded relationship between Canadian companies and the Phoenix-based Translational Genomics Research Institute (TGen).

TD2, TGen's Scottsdale-based drug-development subsidiary, will work with COTI to complete the Investigational New Drug (IND) enabling research necessary to gain U.S. Food and Drug Administration approval of clinical trials, perhaps by the end of 2010, and eventually move the drug to market where it can benefit patients.

COTI-2 works by inducing a brisk apoptotic response the cancer cell kills itself by targeting a pro-survival enzyme family called AKT. Initial tests have shown that COTI-2 can limit the growth of tumors in several types of cancer without the toxic side effects seen in other AKT inhibitors. It also may be even more effective when used in combination with other anti-cancer drugs.

"While traditional cancer chemotherapy is frequently limited by significant toxic side effects, it is drug candidates like COTI-2 that represent a new generation of less toxic drugs with good anti-tumor activity," said Dr. Wayne Danter, COTI's President and Chief Scientific Officer.

COTI-2's development will be guided by Dr. Daniel Von Hoff, TGen's Physician-In-Chief and Senior Investigator of TGen's Clinical Translational Drug Division. Dr. Von Hoff has led the development of numerous successful cancer therapies. Dr. Von Hoff's biography can be found at www.tgen.org/research/index.cfm?pageid=77&peopleid=65.

"I am delighted about our participation in the continued development of this interesting new agent with what appears to be a highly desirable mechanism of action," said Dr. Von Hoff. "I am very hopeful that COTI-2 will have a therapeutic impact in patients with tumors that are non-responsive to conventional therapeutic agents across a number of cancer indications."

Researchers hope to demonstrate that this oral pill will be especially beneficial for patients with small-cell lung cancer (SCLC), endometrial cancer and ovarian cancer, but may also help treat those with colorectal and pancreatic cancers. Collectively, these treatments could represent a worldwide market of more than $20 billion by 2018.

"We are ready to move this exciting new agent to patients quickly and to identify patients most likely to benefit from COTI-2,'' said Dr. Steve Gately, TD2's President and Chief Scientific Officer.

"We are delighted to have the expertise of such a well respected individual as Dr. Von Hoff," said Mr. Michael Cloutier, Chief Executive Officer of COTI. "We believe that affiliating the development of COTI-2 with the scientific expertise of TD2 and Dr. Von Hoff will greatly assist in our commercial efforts. We value the partnership we have with TD2, which allows us to proceed with this program in a step wise fashion as resources become available."

The relationship between TD2 and COTI was initiated at BioPartnering North America 2008 thanks to the Canadian Consulate-Phoenix, which sponsored TGen's participation at the conference. The Canadian Consulate-Phoenix plays a key role in making strategic introductions across Arizona's universities, research facilities, local communities and commercial companies.

"I am thrilled to see this new drug development collaboration between TD2 and an emerging Canadian biotechnology company. The Canada Arizona Business Council hopes that many more will be done,'' said R. Glenn Williamson, Chief Executive Officer and Founder of the Canada Arizona Business Council.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Self-seeding of cancer cells may play a critical role in tumor progression
2. Michael J. Fox Foundation Awards $1 Million for Critical Step Toward Development of Dyskinesia Treatments
3. CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking
4. Bullfrog Spas Helps Critically Ill Children
5. Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs
6. Optimizing Corporate Culture is Critical to the Success of Wellness Programs
7. Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss
8. Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis
9. New Jersey Soccer Coach Hopes for Thanksgiving Miracle for Local Mom - Tournament to Raise Funds for Her Critically Ill Baby
10. AARP Commends Legislature For Saving Critical Health Care Program
11. Protein critical for insulin secretion may be contributor to diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly ... Dyer started as the Chairman of the Management Committee when IFN was originally ... including the recruitment of investor/owners and development of the business plan. He became ...
(Date:2/24/2017)... ... 24, 2017 , ... Rosica Communications, a national PR ... media relations, social media, content marketing and SEO, is now offering direct, social ... intuitive marketing automation platform. , Rosica will now offer the platform to its ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
(Date:2/23/2017)... ... 2017 , ... On February 22, 2017 the U.S. Department ... withdraw previous guidance issued by the Obama Administration requiring schools to treat transgender ... by the Obama Administration came in response to a growing number of states ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/23/2017)... -- Visiomed, the French leader in medical grade ... the landscape of healthcare with their innovative use ... solutions. Recognizing the rising demand of self-monitoring alongside ... walls, Visiomed has launched BewellConnect, the most ground-breaking ... that is empowering the lives of patients. ...
(Date:2/23/2017)... , Feb. 23, 2017 ITL Limited, ( ASX: ITD ... results for the half year ended 31 December 2016 compared with ... Update" presentation can be viewed here . ... 2015: $1.04m; up 104%) Earnings per share of ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
Breaking Medicine Technology: